Capital flows from eager mainland China-based investors are flowing into these artificial intelligence plays.
JPMorgan’s top short ideas for 2026
As the first quarter kicks off, JPMorgan is bearish on names such as Bumble and Fortinet.
Activist Engaged Capital is poised to shake up the board at BlackLine. How it may unfold
A shake-up of BlackLine’s board of directors could be in the cards.
These stocks reporting earnings next week are usually winning bets
Companies reporting their financial results next week, including F5 and Western Alliance, have histories of topping estimates and notching post-earnings gains.
Newmont tops the list of most overbought stocks on Wall Street after gold rally
Newmont, Sandisk and AMD are among the S&P 500’s most overbought stocks this week as measured by their 14-day relative strength index, or RSI.
Flocking to precious metal ETFs? Keep an eye out for these tax surprises
Precious metals are rallying, but investors who are buying into the trade could be in for some tax complexity.
Intel’s likely to still move higher. Here’s a ‘no-cost’ options strategy to play it
Intel is an essential name to the U.S. economy and the “Soprano-like” equity ownership by the government makes me want to own this company for the long haul.
JPMorgan upgrades consumer goods stock on confidence in second-half acceleration
JPMorgan sees shares of Procter & Gamble rising 11% from current levels.
Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts
Roth’s $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.
Intel’s earnings beat couldn’t offset a weaker-than-expected outlook. Here’s what analysts are saying
For the most part, Wall Street analysts maintained a hold-equivalent rating on Intel after supply constraints weighed on the company’s current-quarter outlook.